Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 20377409.
- Also identified by DOI 10.1086/652150.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Three years after measles, mumps, and rubella revaccination in 38 human immunodeficiency virus-infected children who had achieved immune recovery after antiretroviral therapy, the prevalence of protective antibody levels was 85% for measles, 61% for mumps, and 79% for rubella, compared with 88%, 84%, and 100%, respectively, 1 month after revaccination.
Medical subject headings
- Antibodies, Viral
- HIV Infections
- Immunization, Secondary
- Measles
- Mumps
- Rubella